{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:00:32Z","timestamp":1790672432801,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized, treatable, and still underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) and unexplained left ventricular hypertrophy in older adults, with a typical diagnostic delay of several years. We conducted a narrative review with a systematic literature search of PubMed and Embase (January 2000 to June 2026) using database-specific controlled vocabulary and free-text terms related to ATTR cardiomyopathy, clinical red flags, bone scintigraphy, monoclonal protein testing, cardiac magnetic resonance, tafamidis, acoramidis, vutrisiran, and emerging TTR-directed therapies. Two authors screened titles and abstracts, resolved disagreements by consensus, and prioritized multicenter cohorts, clinical trials, meta-analyses, systematic reviews, and guideline or consensus documents. Sixty-two references were included. Three practice points emerge from the literature. First, suspicion should be triggered by red flags such as bilateral carpal tunnel syndrome, lumbar spinal stenosis, spontaneous distal biceps tendon rupture, and the combination of increased ventricular wall thickness with low or normal QRS voltage. Second, the contemporary diagnostic pathway requires parallel bone scintigraphy and complete monoclonal protein screening; grade 2-3 myocardial uptake supports non-biopsy diagnosis of ATTR-CM only when monoclonal screening is negative and myocardial uptake is confirmed, preferably by SPECT or SPECT\/CT. Third, treatment options now extend beyond tafamidis to acoramidis and vutrisiran, with amyloid-depleting antibodies under active investigation. We propose a pragmatic, resource-stratified diagnostic framework for targeted case-finding rather than population-level screening.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1935800","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:10:26Z","timestamp":1790669426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhengjun","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fuling People\u2019s Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Meishan People\u2019s Hospital","place":["Meishan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fuling People\u2019s Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: tHAOS registry","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.09.005","article-title":"ATTR amyloidosis: current and emerging management strategies","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.echo.2019.03.005","article-title":"Role of right ventricular strain measured by two-dimensional echocardiography in the diagnosis of cardiac amyloidosis","volume":"32","author":"Mo\u00f1ivas Palomero","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.rec.2024.07.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","volume":"78","author":"Garc\u00eda-Pav\u00eda","year":"2025","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"258","author":"Sekijima","year":"2011","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.jacc.2022.02.045","article-title":"Transthyretin amyloidosis and carpal tunnel syndrome: a population-based study","volume":"79","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40120-021-00318-2","article-title":"The effectiveness of tafamidis in TTR-FAP: analysis of the THAOS registry","volume":"11","author":"Mundayat","year":"2022","journal-title":"Neurol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-ACT)","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.121.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.3390\/biomedicines10123226","article-title":"Transthyretin cardiac amyloidosis: a cardio-orthopedic disease","volume":"10","author":"Perfetto","year":"2022","journal-title":"Biomedicines"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2016.1136800","article-title":"Carpal tunnel syndrome as the initial symptom of wild-type ATTR amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.humpath.2010.11.017","article-title":"Wild-type transthyretin-derived amyloidosis in various ligaments and tendons","volume":"42","author":"Sueyoshi","year":"2011","journal-title":"Hum Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.920450","article-title":"Transthyretin-derived amyloid in lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cardfail.2022.10.431","article-title":"Biceps tendon rupture: a clue for cardiac amyloidosis","volume":"29","author":"Rao","year":"2023","journal-title":"J Card Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/joim.13200","article-title":"Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype","volume":"289","author":"Cappelli","year":"2021","journal-title":"J Intern Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.002","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0195-5","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102905","DOI":"10.1016\/j.autneu.2021.102905","article-title":"Autonomic dysfunction in transthyretin amyloidosis","volume":"237","author":"Gonzalez-Duarte","year":"2022","journal-title":"Auton Neurosci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"B35","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/heartjnl-2015-308657","article-title":"Prognostic implication of relative regional strain ratio in cardiac amyloidosis","volume":"102","author":"Senapati","year":"2016","journal-title":"Heart"},{"key":"B36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1253\/circj.CJ-20-1064","article-title":"Value of longitudinal strain to identify wild-type transthyretin amyloidosis in patients with aortic stenosis","volume":"85","author":"Robin","year":"2021","journal-title":"Circ J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.amjcard.2005.07.020","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"96","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"B45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast CMR study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"B46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/bjh.14587","article-title":"Prognosis and risk assessment in AL amyloidosis \u2013 there and back again","volume":"178","author":"Kastritis","year":"2017","journal-title":"Br J Haematol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamacardio.2023.1783","article-title":"Tafamidis treatment across the spectrum of transthyretin cardiac amyloidosis disease severity","volume":"8","author":"Rosenblum","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2309138","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy (ATTRibute-CM)","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (HELIOS-B)","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2300772","article-title":"Patisiran in patients with transthyretin cardiac amyloidosis: the APOLLO-B trial","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1007\/s00415-024-12616-6","article-title":"Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform","volume":"271","author":"Concei\u00e7\u00e3o","year":"2024","journal-title":"J Neurol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1161\/CIRCULATIONAHA.125.077304","article-title":"Coramitug, a humanized monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy: a phase 2, randomized, multicenter, double-blind, placebo-controlled trial","volume":"153","author":"Fontana","year":"2026","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/s41591-026-04487-3","article-title":"Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial","volume":"32","author":"Kahr","year":"2026","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000698","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: 20-year results","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin cardiac amyloidosis in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1935800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:10:28Z","timestamp":1790669428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1935800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":62,"alternative-id":["10.3389\/fcvm.2026.1935800"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1935800","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1935800"}}